Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 89 results for vte

  1. The geko device for reducing the risk of venous thromboembolism (MTG19)

    Evidence-based recommendations on the geko device for reducing the risk of venous thromboembolism.

  2. What is the effectiveness and safety of extended pharmacological venous thromboembolism (VTE) prophylaxis for people who have been discharged after treatment for COVID-19?

    What is the effectiveness and safety of extended pharmacological venous thromboembolism (VTE) prophylaxis for people who...

  3. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

    Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein thrombosis or pulmonary embolism in adults.

  4. Risk assessment:- What is the accuracy of individual risk assessment tools in predicting the risk of venousthromboembolism (VTE) and risk of bleeding in people admitted to hospital?

    individual risk assessment tools in predicting the risk of venousthromboembolism (VTE) and risk of bleeding in people admitted to...

  5. Direct oral anticoagulants for people with lower limb immobilisation:- What is the clinical and cost effectiveness of direct oral anticoagulants for preventing VTE in people with lower limb immobilisation?

    clinical and cost effectiveness of direct oral anticoagulants for preventing VTE in people with lower limb immobilisation? Any...

  6. What is the effectiveness and safety of a treatment dose with a low molecular weight heparin (LMWHs) compared with a standard prophylactic dose for venous thromboembolism (VTE) prophylaxis in young people under 18 years with COVID-19?

    heparin (LMWHs) compared with a standard prophylactic dose for venous thromboembolism (VTE) prophylaxis in young people...

  7. Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management (NG228)

    This guideline covers diagnosing and treating an aneurysmal (caused by a ruptured aneurysm) subarachnoid haemorrhage and its complications. It provides recommendations to improve diagnosis and ensure that the most effective treatments are offered. It includes guidance on follow-up care and information for people (aged 16 and over) who have had an aneurysmal subarachnoid haemorrhage, their families and carers.

  8. Abortion care (NG140)

    This guideline covers care for women of any age (including girls and young women under 18) who request an abortion. It aims to improve the organisation of services and make them easier for women to access. Detailed recommendations on conducting abortions at different gestational stages are also included, to ensure that women get the safest and most effective care possible.

  9. Duration of prophylaxis for elective total hip replacement surgery:- What is the clinical and cost effectiveness of standard versus extended duration pharmacological prophylaxis for preventing VTE in people undergoing elective total hip replacement surgery?

    standard versus extended duration pharmacological prophylaxis for preventing VTE in people undergoing elective total hip replacement...

  10. Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)

    Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.

  11. Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

    Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.

  12. Antenatal care (NG201)

    This guideline covers the routine antenatal care that women and their babies should receive. It aims to ensure that pregnant women are offered regular check-ups, information and support.

  13. Myeloma: diagnosis and management (NG35)

    This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

  14. Venous thromboembolism (VTE) - ximelagatran [ID396]

    Discontinued [GID-TAG378]